Abstract: The invention relates to a monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. The invention also relates to a nucleic acid encoding said antibody or antigen-binding fragment thereof, an expression vector, a method for preparing said antibody, and use of said antibody in treatment of diseases or disorders associated with the human T cell receptor family. The invention is directed to generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.

Abstract: Provided are methods of clinical treatment of chronic lymphoblastic leukemia (CLL) in human subjects using a bispecific antibody which binds to CD3 and CD20.

Abstract: Provided herein, in certain aspects, are antibodies that bind to CD8, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are antibodies that bind to CD4, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are multispecific antibodies that bind to CD4 and CD8, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making the antibodies are also provided.

Abstract: The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.

Abstract: The present disclosure provides isolated binding molecules that bind to and blocks PD-L1, vectors comprising a nucleic acid molecules encoding an amino acid sequence of the binding molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring stimulation of immune responses including cancer.

Abstract: Antibodies, and antigen-binding fragments thereof, that specifically bind to Cluster of Differentiation 1a (CD1a) are provided. Embodiments include uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.

Abstract: Antibodies that specifically bind to CLL-1 are described, as well as methods of making and using such antibodies. In one aspect, the present disclosure provides, among other things, antibodies, or antigen binding fragments thereof, that bind (e.g., selectively bind) CLL-1, compositions useful for binding CLL-1, and methods for treating disease comprising administration of such antibodies, or antigen binding fragments thereof.

Abstract: The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and activate LEPR signaling. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR and enhance sensitization of LEPR to an antigen. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence and absence of leptin. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that induce signaling in cells expressing LEPR mutants that otherwise exhibit defective or impaired signaling in the presence of leptin.

Abstract: The present invention relates to methods of treating Type 2 diabetes (T2D), comprising administering to a patient an effective amount of an isolated antagonistic antigen binding protein that specifically binds to the human glucagon receptor, either as monotherapy, or in combination with one or more antidiabetic medications.

Abstract: Provided are compositions and methods relating to human CD30L antigen binding proteins Compositions described herein include: human CD30L antigen binding proteins, polynucleotides encoding human CD30L antigen binding proteins, vectors comprising these polynucleotides, host cells, and pharmaceutical compositions Methods of making and using each of these compositions are also provided.

Abstract: An antigen-binding molecule capable of binding to multiple different antigens (e.g., CD3 on T cells, and CD137 on T cells, NK cells, DC cells, and/or the like), but does not nonspecifically crosslink two or more immune cells such as T cells is provided. Such multispecific antigen-binding molecule is capable of modulating and/or activating an immune response while circumventing the cross-linking between different cells (e.g., different T cells) resulting from the binding of a conventional multispecific antigen-binding molecule to antigens expressed on the different cells, which is considered to be responsible for adverse reactions when the multispecific antigen-binding molecule is used as a drug.

Abstract: Provided herein are B cell maturation agent (BCMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to BCMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such BCMA targeting trispecific proteins. Also disclosed are methods of using the disclosed BCMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.

Abstract: The present invention relates to novel anti-CD40 antibodies and a use thereof and, more specifically, provided are a pharmaceutical composition for treating or preventing autoimmune diseases and a composition for inhibiting immune rejection during organ transplantation, both compositions containing, as an active ingredient, novel anti-CD40 antibodies that specifically bind to a novel epitope of CD40. Novel anti-CD40 antibodies of the present invention directly target CD40, but not CD40 ligands, and block the signaling of CD40-CD154 without stimulating platelets so as to exhibit excellent antagonistic effects, thereby being expected to be usable as a preparation effective in the treatment of autoimmune diseases and the inhibition of organ transplantation rejection.

Abstract: The invention provides agonistic TNFR2 antibodies and antigen-binding fragments thereof and encompasses the use of these antibodies as therapeutics to promote the proliferation of regulatory T cells (T-reg) for the treatment of immunological diseases. Antibodies of the invention can be used to potentiate the T-reg-mediated deactivation of self- and allergen-reactive T- and B-lymphocytes, and can thus be used to treat a wide variety of indications, including autoimmune diseases, allergic reactions, asthma, graft-versus-host disease, and allograft rejection, among others.

Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.

Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).

Abstract: Provided herein are tetravalent antibodies that specifically bind to human PSGL-1. Unlike bivalent antibodies, these tetravalent antibodies contain a dimer of two monomers, with each monomer comprising two light chain variable (VL) domains and two heavy chain variable (VH) domains. This format allows for cross-linker/FcR-expressing cell-independent tetravalent antibodies against PSGL-1 that show enhanced efficacy as compared to bivalent PSGL-1 antibodies. These tetravalent antibodies can be used in a variety of diagnostic and therapeutic methods, including without limitation treating T-cell mediated inflammatory diseases, transplantations, and transfusions.

Abstract: An anti-CD24 antibody is provided. Accordingly, there is provided an antibody comprising an antigen recognition domain which specifically binds CD24 and comprises complementarity determining regions (CDRs) as set forth in SEQ ID NOs: 2, 3 and 4 arranged in a sequential order from N to C on a light chain of the antibody and CDRs as set forth in SEQ ID NOs: 6, 7 and 8 arranged in a sequential order from N to C on a heavy chain of said antibody. Also provided are polynucleotides encoding the antibody, host cells expressing the antibody the uses thereof.

Abstract: The present disclosure provides novel anti-OX40 antibodies, compositions including the antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.

Abstract: The invention relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.

Abstract: Provided herein are bispecific antigen-binding molecules that bind HER2 and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human HER2. The bispecific antigen-binding molecules cluster on the surface of HER2 IHC2+ and IHC3+ cells, and are internalized into the cellular lysosomes. Also included are antibody-drug conjugates (ADCs) comprising the antibodies or bispecific antigen-binding molecules provided herein linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treating cancer in a subject by administering to the subject a bispecific antigen-binding molecule or an ADC thereof.

Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.

Abstract: Provided herein are anti-KRas antibodies that bind to mutant KRas-GDP and alkylated mutant KRas-GDP and methods of using the same. Also provide herein are method of screening for KRas inhibitors and methods of measuring binding of KRas to the antibodies described herein.

Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL ineligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of gemcitabine and oxaliplatin (GemOx).

Abstract: A silicon glycan is provided. The silicon glycan comprises a glycoside moiety, independently selected organosilicon moieties, and beta-amino alcohol moieties joining the organosilicon moieties to the glycoside moiety. The glycoside moiety comprises independently selected saccharide moieties, which may be substituted with hydrocarbyl groups, ether moieties, and/or amine moieties. A method of preparing the silicon glycan is also provided. The method includes reacting (A) an aminoethyl polysaccharide and (B) an epoxide-functional organosilicon compound, to give the silicon glycan. The method may include preparing the aminoethyl polysaccharide (A) by first reacting (At) a hydroxyl-functional polysaccharide and (A2) an aziridinium halide compound to give the aminoethyl polysaccharide (A).

Abstract: A process for producing a crosslinked cellulose ether including the steps of: (a) contacting at least one cellulose material with at least one alkalization reagent to form an activated cellulose material; (b) contacting the activated cellulose material of step (a) with at least one etherification reagent to form an uncrosslinked cellulose ether; (c) subjecting the cellulose ether of step (b) to a simultaneous or stepwise washing and/or granulating step; (d) adding at least one crosslinking agent to the uncrosslinked cellulose ether during the washing and/or granulating of step (c) to form a crosslinked cellulose ether; and (e) any other optional components desired; and a crosslinked cellulose ether produced by the above process.

Abstract: The disclosure provides a modified chitosan, a preparation method thereof, and an additive for a tile adhesive, and belongs to the technical field of building additives. In the disclosure, chitosan, an inorganic base, a dispersant having a hydroxyl group and an etherifying agent are added at one time, avoiding the tedious operation of adding inorganic alkali or etherifying agent multiple times. In addition, the etherification reaction is continuously performed under the conditions of gradual temperature increase and pressure increase.

Abstract: The present disclosure discloses an ultrasonic-assisted method of extracting a pectin rich in RG-I. The method includes: (1) dispersing citrus peel powders in an alkaline solution containing sodium borohydride; (2) placing a solution obtained in step (1) in a water bath of 25 to 40° C., and performing an ultrasonic treatment on the solution obtained in step (1); (3) centrifuging the solution subjected to step (2) at a speed of 6000-8000 rpm to remove residues, retaining a supernatant, and precipitating a pectic polysaccharide with absolute ethanol; and (4) adding water to the pectic polysaccharide precipitant subjected to step (3) to obtain a redissolved solution, transferring the solution to a dialysis bag with a molecular weight cut-off of 3000 to 3500 Da, dialyzing for 48 hours, and freeze-drying in a vacuum freezer to obtain the pectin rich in RG-I.

Abstract: The present disclosure discloses a method for extracting pectin rich in RG-I, in particular to an ultrasound and pressure assisted method for extracting pectin rich in RG-I. The main process includes: dispersing sieved citrus peel powers in alkaline solution containing sodium borohydride (20 to 50 mM); performing an ultrasound and pressure combined treatment on the above solution at 25 to 40° C., the treatment conditions include: static pressure of 0.2 to 0.4 MPa, ultrasonic intensity of 0.5 to 3.5 W/mL, and treatment time of 20 to 40 min; centrifuging the ultrasonically processed solution to remove residues, and sequentially carrying out precipitation with ethanol (50% to 80% v/v), precipitant dialysis (3000 to 3500 Da), and vacuum freeze drying on the extracted solution to obtain pectic polysaccharide.

Abstract: Method for obtaining low molecular weight heparins (LMWH) with a weight average molecular weight distribution between 3.0 and 5.0 kDa comprising at least one concentration step by tangential flow filtration (TFF). The method is particularly useful for the preparation of bemiparin and enoxaparin without the use of fractional precipitation nor the use of alcoholic solutions. In particular, the preparation of LMWH is obtained by depolymerization of heparin and filtration (TFF ultrafiltration and/or diafiltration) of the depolymerized heparin without the use of fractional precipitation and without an alcoholic solution.

Abstract: The present invention provides a “living” radical polymerization method for a vinyl monomer by near-infrared photothermal conversion. The method comprises irradiating a reactor with near-infrared light of 750-850 nm, wherein the reactor has a first chamber and a second chamber that are isolated from each other, the first chamber contains an organic solution of a near-infrared light responsive croconaine dye, and the second chamber is provided with a closed reaction flask containing a reaction solution, the reaction solution comprises a vinyl monomer, two or more of an ATRP initiator, an ATRP ligand, an ATRP catalyst, an RAFT reagent, a thermal initiator, and an additive, and an organic solvent; and the near-infrared light responsive dye converts the near-infrared light into heat energy, by which the reactor is heated to 50-100° C. to polymerize the monomer in the reaction solution, to obtain polymers with controlled molecular weights and molecular weight distributions.

Abstract: Reverse iodine transfer polymerization of an ethylenically unsaturated monomer comprising (meth)acrylic acid, salt thereof, or combination thereof, in the presence of a radical polymerization initiator, an oxidant, an iodide salt, and a solvent, is a useful method for making (meth)acrylic acid polymers. The amounts of components utilized can be 5 to 500 equivalents of the ethylenically unsaturated monomer comprising (meth)acrylic acid, salt thereof, or combination thereof, in the presence of 1 to 3 equivalents of the radical polymerization initiator, 0.2 to 1 equivalent of the oxidant, and 1 equivalent of the iodide salt. (Meth)acrylic acid polymer solutions are made by these methods. The (meth)acrylic polymers are useful as dispersants.

Abstract: A resin composition includes: (A) a polybutadiene having a content of 1,2-vinyl group of greater than or equal to 85%; and (B) a styrene-butadiene-styrene triblock copolymer of Formula (1) comprising a butadiene block having a content of 1,2-vinyl group of greater than or equal to 80%. Moreover, an article may be made from the resin composition, which comprises a prepreg, a resin film, a laminate or a printed circuit board. The resin composition or the article made therefrom may achieve improvement in one or more properties including Z-axis ratio of thermal expansion, thermal resistance after moisture absorption, dissipation factor, and dissipation factor aging variation under moisture and heat.

Abstract: A composite film comprises first and second layers. The first layer comprises a first copolymer of monomers comprising tetrafluoroethylene, hexafluoropropylene, and vinylidene fluoride, wherein the first copolymer contains at least 35 mole percent of vinylidene fluoride monomer units. The second layer is disposed on the first layer, and comprises a second copolymer comprising 50 to 83 weight percent of ethylene monomer units and at least 17 weight percent of alkyl (meth)acrylate monomer units represented by the formula (I) wherein R1 is H or methyl, and each R2 is independently an alkyl group having from 1 to 4 carbon atoms. Methods of making the composite film and articles including it are also disclosed.

Abstract: An object of the present invention is to obtain an aqueous thermosetting resin composition capable of obtaining satisfactory curing performance by a transesterification reaction between alkyl ester and a hydroxyl group. The aqueous thermosetting resin composition includes a resin component (A) that has —COOR (R is an alkyl group having 50 or less carbon atoms) and a hydroxyl group and a transesterification catalyst (B).

Abstract: Disclosed is a formulation comprising a copolymer comprising one or more high refractive index first monomers and one or more second monomers comprising a reactive side chain and one or more solvents. The formulation may optionally contain additional components. Further disclosed are methods for forming optical thin films from the formulation and optical devices containing the optical thin films.

Abstract: A composition comprises: a branched organosilicon compound; an acrylate-functional compound other than the branched organosilicon compound; and optionally a carrier vehicle. The branched organosilicon compound has the following general formula (I): (R1)3Si—X (I); where X comprises a acryloxy-functional moiety, and each R1 is selected from —OSi(R4)3 and R, with the proviso that at least one R is —OSi(R4)3; where each R is a substituted or unsubstituted hydrocarbyl group; where each R4 is selected from R, —OSi(R5)3, and —[OSiR2]mOSiR3; where each R5 is selected from R, —OSi(R6)3, and —[OSiR2]mOSiR3; where each R6 is selected from R and —[OSiR2]mOSiR3; with the proviso that at least one of R4, R5 and R6 is —[OSiR2]mOSiR3; and where 0?m?100. A method of preparing a copolymer is further provided.

Abstract: (Meth)acrylate-functionalized branched polyalpha-olefins which are the reaction product of, at least, a) a (meth)acrylate source and b) a hydroxyl-functionalized branched polymerizate of, at least, i) one or more alpha-olefin monomers having at least six carbon atoms per molecule and ii) one or more unsaturated hydroxyl-functionalized comonomers are useful hydrophobic, reactive components of crosslinkable resin compositions additionally containing a polymer (such as a polyolefin) as well as curable compositions containing one or more additional types of (meth)acrylate-functionalized compounds.

Abstract: A polypropylene resin composition is provided that includes an ethylene-propylene block copolymer resin. The ethylene-propylene block copolymer resin comprises a propylene homopolymer component and an ethylene-propylene rubber copolymer component as a solvent extract. The content of the ethylene-propylene rubber copolymer component in the ethylene-propylene block copolymer resin is 25 to 40% by weight. The ratio of the content of ethylene to the content of solvent extract in the ethylene-propylene block copolymer resin based on percent by weight is 0.25 to 0.45/ The ethylene-propylene block copolymer resin has a melt index of 20 to 45 g/10 minutes when measured at 230° C. under a load of 2.16 kg.

Abstract: The present disclosure relates to an expanded foam solution for forming a thermosetting expanded foam having excellent flame retardancy produced using the same. According to the present disclosure, nanoclay is mixed with a polyol-based compound using ultrasonic waves, an isocyanate-based compound is added, and a trimerization catalyst or an isocyanurate compound is mixed with the polyol-based compound so that an isocyanurate structure is formed.

Abstract: A polyurethane foam is produced by reacting a polyol-containing composition and an isocyanate composition. The polyol-containing composition includes a petrol-based polyol, an algae-based polyol, and a soy-based polyol.

Abstract: In the method for producing a spectacle lens, the spectacle lens is a cured product obtained by curing a polymerizable composition containing 5-(isocyanatomethyl)bicyclo[2.2.1]hept-2-ene and one or more polythiol compounds, the method includes preparing the polymerizable composition by a preparation process including a first mixing step of mixing 5-(isocyanatomethyl)bicyclo[2.2.1]hept-2-ene and a polythiol compound with each other in the presence of a first catalyst that catalyzes a thiol-ene reaction, and a second mixing step of mixing a second catalyst that catalyzes a thiourethanization reaction with a mixture obtained in the first mixing step; and subjecting the polymerizable composition to a curing treatment.

Abstract: The present invention provides polyurethanes including a reaction product of components including: (a) an isocyanate functional urethane prepolymer including a reaction product of components including: (i) about 1 equivalent of at least one polyisocyanate; and (ii) about 0.01 to about 0.5 equivalent of at least one polyol having at least 3 hydroxyl groups; and (b) about 0.1 to about 1.0 equivalent of at least one polyol having at least 3 hydroxyl groups; compositions, coatings and articles made therefrom and methods of making the same.

Abstract: A three-dimensional object producing method including: forming a powder material layer with a powder material for three-dimensional object formation, where the powder material includes a base material and a resin including a reactive functional group; and applying a curing liquid to the powder material layer to form a cured product, where the curing liquid contains a curing agent capable of forming a covalent bond with the reactive functional group, wherein the curing agent includes an aliphatic compound having two or more isocyanate groups at a molecular terminal thereof.

Abstract: An objective of the present invention is to provide: a novel thiol compound; a method for synthesizing the thiol compound; a curing agent containing the thiol compound; a resin composition containing the thiol compound and an epoxy compound; and a resin composition containing the thiol compound and an enic compound having an intramolecular carbon-carbon double bond. The thiol compound of the present invention, as exemplified by the compounds listed below, is a reaction product of a certain type of dialkene compound and a thiol compound, and has two or more intramolecular thioether bonds but no ester bonds.

Abstract: Described is a cationic initiator system comprising a cationic initiator; and an accelerator composition comprising 1) a operoxyketal; and 2) an accelerator compound selected from arylhydroxy compounds and ?-diketone compounds.

Abstract: A method of light-promoted frontal ring-opening metathesis polymerization includes providing a monomer solution including dicyclopentadiene, a ruthenium-based catalyst and a phosphite inhibitor, and exposing the monomer solution to ultraviolet light having a wavelength in a range from 315 nm to 400 nm, thereby initiating an exothermic polymerization reaction and generating a self-propagating polymerization front. The polymerization front moves through the monomer solution and polymerizes the dicyclopentadiene.

Abstract: The present disclosure presents a disulfide containing monomer, its reduced form, its derivative, the synthesis method of this disulfide containing monomer, and the polymer containing the monomers disclosed thereof

Abstract: Disclosed herein are catalyst systems useful for a wide range of ring opening polymerization processes. Epoxides, oxetanes, lactones and cyclic carbonates are all suitable substrates for the ring opening polymerization.

Abstract: A terminal-modified polyamide 4 having improved thermal stability is provided. The terminal-modified polyamide 4 consists of a polyamide 4-derived site (A) and a polyalkylenimine-derived site (B), and has a structure in which a polyalkylenimine is amide-bonded to a polymerization terminal of polyamide 4. The weight ratio between the polyamide 4-derived site (A) and the polyalkylenimine-derived site (B) is 100:0.01-100:20. The polyamide 4-derived site (A) is a site derived from polyamide 4 having a number average molecular weight (Mn) of 1,000 to 2,000,000, and the polyalkylenimine-derived site (B) is a site derived from a polyalkylenimine having a number average molecular weight (Mn) of 400 to 100,000.